TherapeuticsMD (NASDAQ:TXMD) Now Covered by StockNews.com

StockNews.com began coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Sunday. The firm issued a hold rating on the stock.

TherapeuticsMD Price Performance

Shares of TXMD opened at $2.14 on Friday. TherapeuticsMD has a fifty-two week low of $1.84 and a fifty-two week high of $4.52. The business has a 50-day moving average of $2.09 and a 200 day moving average of $2.26.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Friday, May 10th. The company reported ($0.07) earnings per share (EPS) for the quarter. The firm had revenue of $0.31 million during the quarter.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently bought a new position in TherapeuticsMD stock. ADAR1 Capital Management LLC purchased a new stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 272,160 shares of the company’s stock, valued at approximately $612,000. ADAR1 Capital Management LLC owned 2.57% of TherapeuticsMD at the end of the most recent quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.